Anuradha Banerjee, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Anuradha Banerjee, MD

Associate Clinical Professor, Departments of Pediatrics and Neurological Surgery, UCSF

banerjee@neurosurg.ucsf.edu

Phone: (415) 353-2880 (voice); (415) 502-3744 (voice)
Box 0372, UCSF
San Francisco, CA 94143-0372

View on UCSF Profiles

Cancer Center Membership

Program Member ยป Pediatric Malignancies

Education

Stanford University, Stanford, CA, A.B., 1987, Human Biology
Tulane University, New Orleans, LA, M.P.H., 1990, Epidemiology
Tulane University, New Orleans, LA, M.D., 1992, Medicine
Univ. of California, San Francisco, San Francisco, CA, Resident, 1995, Pediatrics
San Francisco General Hospital, San Francisco, CA, Chief Resident, 1996, Pediatrics
Univ of California, San Francisco, San Francisco, CA, Clinical Fellow, 1996-99, Pediatric Hematology/Oncology


Professional Experience

  • 1999-2000
    Assistant Clinical Professor of Pediatrics, University of California, San Francisco, CA
  • 2001-2007
    Assistant Professor of Clinical Pediatrics and Neurosurgery, Divisions of Pediatric Oncology and Neuro-oncology, Departments of Pediatrics and Neurological Surgery, University of California, San Francisco
  • 2007-Present
    Associate Clinical Professor of Pediatrics and Neurosurgery, Divisions of Pediatric Oncology and Neuro-oncology, Departments of Pediatrics and Neurological Surgery, University of California, San Francisco

Selected Publications

  1. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst. 2015 Sep; 31(9):1433-45.
    View on PubMed
  2. Metastatic Diffuse Intrinsic Pontine Glioma to the Peritoneal Cavity Via Ventriculoperitoneal Shunt: Case Report and Literature Review. J Neurol Surg Rep. 2015 Jul; 76(1):e91-6.
    View on PubMed
  3. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2015 Feb; 17(2):303-11.
    View on PubMed
  4. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. J Neurooncol. 2015 Jan; 121(1):217-24.
    View on PubMed
  5. Pure germinomas of the central nervous system: treatment strategies and outcomes. J Neurooncol. 2014 Dec; 120(3):643-9.
    View on PubMed
  6. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2014 Jan; 16(2):310-7.
    View on PubMed
  7. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer. 2013 Dec 1; 119(23):4180-7.
    View on PubMed
  8. Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution. Clin Ophthalmol. 2013; 7:981-9.
    View on PubMed
  9. Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Childs Nerv Syst. 2013 Aug; 29(8):1313-9.
    View on PubMed
  10. Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. Neuro Oncol. 2013 Jun; 15(6):759-66.
    View on PubMed
  11. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. J Neurooncol. 2012 Dec; 110(3):305-13.
    View on PubMed
  12. Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). J Neurooncol. 2012 Sep; 109(3):565-71.
    View on PubMed
  13. The superiority of conservative resection and adjuvant radiation for craniopharyngiomas. J Neurooncol. 2012 May; 108(1):133-9.
    View on PubMed
  14. An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. J Neurooncol. 2012 May; 108(1):29-35.
    View on PubMed
  15. Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy. J Neurooncol. 2012 Jan; 106(2):367-75.
    View on PubMed
  16. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet. 2011 May 15; 157C(2):136-46.
    View on PubMed
  17. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011 Mar; 13(3):298-306.
    View on PubMed
  18. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2011 Mar; 13(3):290-7.
    View on PubMed
  19. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010 Dec; 46(18):3287-93.
    View on PubMed
  20. Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J Neurooncol. 2010 Oct; 100(1):121-7.
    View on PubMed

Go to UCSF Profiles, powered by CTSI